期刊
FUTURE ONCOLOGY
卷 12, 期 5, 页码 607-616出版社
FUTURE MEDICINE LTD
DOI: 10.2217/fon.15.351
关键词
castration-resistant prostate cancer; enzalutamide; hormone-sensitive prostate cancer; prostate cancer; STRIVE
类别
资金
- Pierre Fabre
- Astellas Pharma
- Pfizer
- Takeda/Millennium
The field of prostate cancer has witnessed incredible progress in the last decade, owing to the approval of multiple survival-prolonging treatments for metastatic castration-resistant prostate cancer (mCRPC). Enzalutamide is a nonsteroidal androgen receptor inhibitor that targets multiple steps in the androgen receptor signaling axis. It has been approved for the treatment of mCRPC both in the postdocetaxel and in the chemotherapy-naive settings. We summarize the milestones in the development of enzalutamide in patients with prostate cancer. Special focus is placed on the results of the STRIVE Phase II clinical trial comparing head to head enzalutamide and bicalutamide in patients with nonmetastatic and mCRPC who have failed androgen deprivation and in other ongoing trials in the same setting and in earlier disease phases.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据